Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal

Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $4.9 billion.

Alpine develops immunotherapies to address cancer, kidney disease, and other serious autoimmune and inflammatory conditions by engineering proteins that influence the body’s immune response.

“This is a historic moment for Alpine, for our employees, and most importantly, for patients who may benefit from our pipeline of products,” said Mitchell Gold, the company’s CEO.

READ THE STORY at GeekWire »